Pfizer gets FDA nod for Xeljanz to treat juvenile idiopathic arthritis

Pfizer gets FDA nod for Xeljanz to treat juvenile idiopathic arthritis

Source: 
Pharmaceutical Business Review
snippet: 

Pfizer has secured approval from the US Food and Drug Administration (FDA) for its Xeljanz (tofacitinib) to treat children and adolescents two years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA).